Imcyse is a clinical-stage biopharmaceutical company pioneering the development of a new class of active, specific immunotherapies for the treatment of severe, chronic autoimmune diseases.
The Imcyse technology platform has the potential to address a wide range of indications in the vast field of immunology. It is based on the discovery of modified synthetic peptides - Imotopes, which specifically block improper immune responses. Thus representing a next generation, potentially curative approach to severe chronic autoimmune diseases for which there is no satisfactory therapeutic alternative.
The company has established proof of concept in several indications and has completed its first clinical trial in type 1 diabetes with promising results. Beyond type 1 diabetes, we have initiated our first clinical study in multiple sclerosis and are developing a pipeline of ImotopesTM for the treatment of several autoimmune diseases including rheumatoid arthritis, neuromyelitis optica and celiac disease.
Discover our Corporate Presentation here